Antitumor activity of cytokine-induced killer cells against human lung cancer

Hwan Mook Kim; Jaeseung Lim; Song Kyu Park; Jong Soon Kang; Kiho Lee; Chang Woo Lee; Ki Hoon Lee; Mi Jung Yun; Kyu Hwan Yang; Gyoonhee Han; Soon Woo Kwon; Youngsoo Kim; Sang Bae Han

doi:10.1016/j.intimp.2007.08.016

Antitumor activity of cytokine-induced killer cells against human lung cancer

Hwan Mook Kim, Jaeseung Lim, Song Kyu Park, Jong Soon Kang, Kiho Lee, Chang Woo Lee, Ki Hoon Lee, Mi Jung Yun, Kyu Hwan Yang, Gyoonhee Han, Soon Woo Kwon, Youngsoo Kim, Sang Bae Han

Research output: Contribution to journal › Article › peer-review

51 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related death among men and women in the world. Despite the aggressive treatment with surgery, radiation and chemotherapy, the long term survival for lung cancer patients remains low. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human lung cancer was evaluated in vitro and in vivo. Although CD3⁺CD56⁺ CIK cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 98% of NCI-H460 human lung cancer cells, which was determined by the ⁵¹Cr-release assay. In addition, CIK cells at doses of 3 and 30 million cells per mouse inhibited 57% and 77% of NCI-H460 tumor growth in nude mouse xenograft assay, respectively. This study suggests that CD3⁺CD56⁺ CIK cells may be used as an adoptive immunotherapy for patients with lung cancer.

Original language	English
Pages (from-to)	1802-1807
Number of pages	6
Journal	International Immunopharmacology
Volume	7
Issue number	13
DOIs	https://doi.org/10.1016/j.intimp.2007.08.016
Publication status	Published - 2007 Dec 15

Bibliographical note

Funding Information:
This research was partially supported by a grant from the KRIBB Research Initiative Program and by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.intimp.2007.08.016

Cite this

@article{7256c824fc124e87a481b40012d7e715,

title = "Antitumor activity of cytokine-induced killer cells against human lung cancer",

abstract = "Lung cancer is the leading cause of cancer-related death among men and women in the world. Despite the aggressive treatment with surgery, radiation and chemotherapy, the long term survival for lung cancer patients remains low. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human lung cancer was evaluated in vitro and in vivo. Although CD3+CD56+ CIK cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 98% of NCI-H460 human lung cancer cells, which was determined by the 51Cr-release assay. In addition, CIK cells at doses of 3 and 30 million cells per mouse inhibited 57% and 77% of NCI-H460 tumor growth in nude mouse xenograft assay, respectively. This study suggests that CD3+CD56+ CIK cells may be used as an adoptive immunotherapy for patients with lung cancer.",

author = "Kim, {Hwan Mook} and Jaeseung Lim and Park, {Song Kyu} and Kang, {Jong Soon} and Kiho Lee and Lee, {Chang Woo} and Lee, {Ki Hoon} and Yun, {Mi Jung} and Yang, {Kyu Hwan} and Gyoonhee Han and Kwon, {Soon Woo} and Youngsoo Kim and Han, {Sang Bae}",

note = "Funding Information: This research was partially supported by a grant from the KRIBB Research Initiative Program and by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).",

year = "2007",

month = dec,

day = "15",

doi = "10.1016/j.intimp.2007.08.016",

language = "English",

volume = "7",

pages = "1802--1807",

journal = "International Immunopharmacology",

issn = "1567-5769",

publisher = "Elsevier",

number = "13",

}

TY - JOUR

T1 - Antitumor activity of cytokine-induced killer cells against human lung cancer

AU - Kim, Hwan Mook

AU - Lim, Jaeseung

AU - Park, Song Kyu

AU - Kang, Jong Soon

AU - Lee, Kiho

AU - Lee, Chang Woo

AU - Lee, Ki Hoon

AU - Yun, Mi Jung

AU - Yang, Kyu Hwan

AU - Han, Gyoonhee

AU - Kwon, Soon Woo

AU - Kim, Youngsoo

AU - Han, Sang Bae

N1 - Funding Information: This research was partially supported by a grant from the KRIBB Research Initiative Program and by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).

PY - 2007/12/15

Y1 - 2007/12/15

N2 - Lung cancer is the leading cause of cancer-related death among men and women in the world. Despite the aggressive treatment with surgery, radiation and chemotherapy, the long term survival for lung cancer patients remains low. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human lung cancer was evaluated in vitro and in vivo. Although CD3+CD56+ CIK cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 98% of NCI-H460 human lung cancer cells, which was determined by the 51Cr-release assay. In addition, CIK cells at doses of 3 and 30 million cells per mouse inhibited 57% and 77% of NCI-H460 tumor growth in nude mouse xenograft assay, respectively. This study suggests that CD3+CD56+ CIK cells may be used as an adoptive immunotherapy for patients with lung cancer.

AB - Lung cancer is the leading cause of cancer-related death among men and women in the world. Despite the aggressive treatment with surgery, radiation and chemotherapy, the long term survival for lung cancer patients remains low. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human lung cancer was evaluated in vitro and in vivo. Although CD3+CD56+ CIK cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 98% of NCI-H460 human lung cancer cells, which was determined by the 51Cr-release assay. In addition, CIK cells at doses of 3 and 30 million cells per mouse inhibited 57% and 77% of NCI-H460 tumor growth in nude mouse xenograft assay, respectively. This study suggests that CD3+CD56+ CIK cells may be used as an adoptive immunotherapy for patients with lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=35848940733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848940733&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2007.08.016

DO - 10.1016/j.intimp.2007.08.016

M3 - Article

C2 - 17996691

AN - SCOPUS:35848940733

SN - 1567-5769

VL - 7

SP - 1802

EP - 1807

JO - International Immunopharmacology

JF - International Immunopharmacology

IS - 13

ER -

Antitumor activity of cytokine-induced killer cells against human lung cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this